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Abstract
Background: Uterine temporal and dose-dependent histopathologic, morphometric and gene
expression responses to the selective estrogen receptor modulator tamoxifen (TAM) were
comprehensively examined to further elucidate its estrogen receptor-mediated effects. These
results were systematically compared to the effects elicited by the potent estrogen receptor ligand
17α-ethynylestradiol (EE) to identify pathways similarly and uniquely modified by each compound.
Results: Three daily doses of 100 µg/kg TAM elicited a dose-dependent increase in uterine wet
weight (UWW) in immature, ovariectomized C57BL/6 mice at 72 hrs with concurrent increases in
luminal epithelial cell height (LECH), luminal circumference and glandular epithelial tubule number.
Significant UWW and LECH increases were detected at 24 hrs after a single dose of 100 µg/kg
TAM. cDNA microarray analysis identified 2235 differentially expressed genes following a single
dose of 100 µg/kg TAM at 2, 4, 8, 12, 18 and 24 hrs, and at 72 hrs after three daily doses (3 × 24
hrs). Functional annotation of differentially expressed genes was associated with cell growth and
proliferation, cytoskeletal organization, extracellular matrix modification, nucleotide synthesis,
DNA replication, protein synthesis and turnover, lipid metabolism, glycolysis and immunological
responses as is expected from the uterotrophic response. Comparative analysis of TAM and EE
treatments identified 1209 common, differentially expressed genes, the majority of which exhibited
similar profiles despite a temporal delay in TAM elicited responses. However, several conserved
and treatment specific responses were identified that are consistent with proliferation (Fos,
Cdkn1a, Anapc1), and water imbibition (Slc30a3, Slc30a5) responses elicited by EE.
Conclusion:  Overall, TAM and EE share similar gene expression profiles. However, TAM
responses exhibit lower efficacy, while responses unique to EE are consistent with the physiological
differences elicited between compounds.
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Background
Tamoxifen (TAM) treatment is an adjuvant therapy pre-
scribed for estrogen receptor positive breast cancers. TAM
and its metabolites, 4-hydroxytamoxifen (4OH-TAM), N-
desmethyltamoxifen (DMT) and 4-OH-N-desmethylta-
moxifen (endoxifen), exhibit antiestrogenic activities by
competitively inhibiting the binding of potent agonists to
the estrogen receptor (ER) thus antagonizing their prolif-
erative effects [1-4]. Despite the high therapeutic index of
TAM for breast cancer, there are concerns regarding the
increased occurrence of uterine cancer as early as 2 years
after initiating treatment [5]. Although there is no direct
evidence that it initiates or promotes uterine cancer, TAM
exhibits partial ER-agonist activity by inducing uterotro-
phy in immature and ovariectomized rodents [6,7]. Con-
sequently, a more comprehensive comparison to full
agonists is warranted to further elucidate the uterine gene
expression effects responsible for its partial agonist activ-
ity.
TAM is classified as a selective estrogen receptor modula-
tor (SERM) as a result of its differential effects in breast
and uterine tissues [8]. A number of factors influence the
specificity and efficacy of SERM-bound, ER-mediated gene
expression, and the subsequent physiological effects. This
includes differences in tissue-specific ER isoform expres-
sion levels, ligand-induced ER topology, chromatin struc-
ture, and coactivator expression and distribution [9,10],
thus making the ER an ideal target for drug discovery and
development. For example, raloxifene, a second-genera-
tion SERM, has been approved for osteoporosis and stud-
ies also support its use for breast cancer [11].
The uterotrophic assay is a well established method to
evaluate the estrogenicity of a compound as measured by
ER-mediated increases in uterine wet weight making it an
ideal model for comparing 17α-ethynylestradiol (EE) and
TAM elicited effects [12]. The uterotrophic response also
provides well characterized phenotypic hallmarks that
facilitate the interpretation of gene expression changes
and their function. Early studies have shown that TAM
elicits a weaker uterotrophic response than 17β-estradiol
(E2) in an immature rodent model [13], however, the
mechanisms for its partial agonist activity are not well
understood.
Genome-wide expression analysis, phenotypically
anchored to tissue level effects, provides a comprehensive
strategy to identify differential gene expression important
in the ER-induction of uterine wet weight. In this report,
we extend previous studies examining ER-mediated
induction of uterine wet weight [14-16] by identifying
conserved and divergent uterine tissue and gene expres-
sion responses elicited by TAM when compared to EE, an
orally active full agonist that mimics the effects of E2 [17].
Comparative analysis found conserved gene expression
responses that exhibited lower efficacy, consistent with
the weak agonist activity of TAM, as well as divergent
responses unique to EE that partially explain the lack of
TAM-induced water imbibition.
Results
Uterine weight
Increases in uterine wet weight (UWW) in rodents after
three daily subcutaneous doses of TAM is well docu-
mented [18,19]. Dose-dependent increases in uterine
weight (EC50 = 33.7 µg/kg) were observed following three
consecutive daily oral treatments of TAM (Figure 1A),
however induction plateaued at 5-fold, compared to 11-
fold with an equivalent dose of 100 µg/kg 17α-ethy-
nylestradiol (EE) [16]. Comparison of wet and blotted
uterine weights indicated no significant water imbibition
in TAM-treated uteri. However, blotted EE-treated uteri
were larger, consistent with past reports that TAM induces
a less efficacious uterotrophic effect [20]. In order to
establish a temporal profile, the uterotrophic effects of
100 µg/kg TAM were also investigated at 2, 4, 8, 12, 18, 24
and 3 × 24 hrs. A significant 2.5-fold increase was
observed at 24 hrs after a single 100 µg/kg TAM dose (Fig-
ure 1B) which was delayed compared to the significant
increase seen with 100 µg/kg EE at 18 hrs [16].
Morphometric analysis and histopathology
Luminal epithelial cell height (LECH), luminal circumfer-
ence and number of endometrial glands are hallmarks of
estrogen action in the rodent which correlate with UWW
induction [21]. Significant dose-dependent increases in
LECH and luminal circumference were initially detected
at 30 µg/kg TAM (Table 1A). Interestingly, LECH was not
significantly different between 100 µg/kg EE and TAM,
although the luminal circumference of EE uteri was
greater with more pronounced invagination of the lumi-
nal glandular epithelium (Figure 2). There was also mild
to moderate hypertrophy in the stromal nuclei at 10 µg/kg
TAM with moderate epithelial hypertrophy and hyperpla-
sia at 30 µg/kg TAM, which was marked at higher doses.
Mild edema was noted for all samples beginning at 100
µg/kg TAM. Marked to severe stromal nuclei hypertrophy
and epithelial hypertrophy and hyperplasia, all with mild
edema, was observed at 100 µg/kg EE. Mild to moderate
stromal edema was observed as early as 12 hrs following
after a single 100 µg/kg TAM dose, while increased UWW
and LECH were not significant until 24 hrs (Table 1B). No
significant increase in luminal circumference was
observed in the first 24 hrs after treatment.
Uterine endometrial glands synthesize and secrete fluids
in preparation for conceptus, implantation and growth.
Significant increases in the number of glands was
observed at 30 µg/kg TAM (Table 1A) in the absence of aBMC Genomics 2007, 8:151 http://www.biomedcentral.com/1471-2164/8/151
Page 3 of 15
(page number not for citation purposes)
Tamoxifen-induced dose dependent and temporal changes in  uterine weight Figure 1
Tamoxifen-induced dose dependent and temporal 
changes in uterine weight. Graphs illustrate fold-change 
increases in uterine wet (open) and blotted (solid) weight. A) 
Tamoxifen elicits a dose dependent uterotrophic response 
(EC50 = 33.7 µg/kg) and achieves maximal induction of 
approximately 5-fold following three daily doses (3 × 24 hrs) 
of 100 µg/kg TAM. Significant increases (p < 0.05, n = 5) are 
denoted by an asterisk (*). In contrast, 100 µg/kg EE (positive 
control) maximally induced uterine wet weight 11-fold (*, p < 
0.05, n = 5) with significant water imbibition (#; p < 0.05, n = 
3), while TAM only achieved 50% uterotrophic efficacy and 
no water imbibition. B) A single dose of 100 µg/kg TAM sig-
nificantly increased uterine wet weight as early as 24 hrs after 
administration. No significant water imbibition was observed 
at any time point.
Uterine histology Figure 2
Uterine histology. Hematoxylin and eosin stained sections 
of uterine tissue at 100× magnification after three daily doses 
of A) sesame oil, B) 1 mg/kg TAM and C) 100 µg/kg EE. TAM 
and EE treatment induced increases in luminal epithelial cell 
height. Luminal circumference is increased to a greater 
degree by EE than TAM. Bars represent 20 µm.BMC Genomics 2007, 8:151 http://www.biomedcentral.com/1471-2164/8/151
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dose responsive increase, which may be an artifact of his-
tological sampling of the uterine horn. Similarly, EE-
treated uteri exhibited an increased number of endome-
trial glands that was not statistically significant.
Uterine gene expression changes elicited by tamoxifen
Differentially expressed genes in the dose and time
dependent studies were identified based on their empiri-
cal Bayes posterior probability of activity [P1(t)-value] on
a per-gene, per-time point basis. P1(t)-values approaching
1.0 indicate a greater likelihood of treatment-related dif-
ferential gene expression. Using P1(t) > 0.999 and |fold
change| ≥ 1.5 as selection criteria, a prioritized list of 2941
features, representing 2235 unique Entrez Gene anno-
tated genes, were identified in the temporal study with
55% of the genes exhibiting induction and 45% repres-
sion (Additional file 1). Differential expression levels
ranged from 14.3-fold repression (tight junction protein
4, Tjp4) to 28.1-fold induction (arginase 1, Arg1), further
demonstrating the responsiveness of the uterus to
tamoxifen. Using the same selection criteria (P1(t) >
0.999 and |fold change| of ≥ 1.5) at a minimum of three
doses, to ensure dose responsiveness, 1630 features, rep-
resenting 1036 unique Entrez Gene-annotated genes,
exhibited dose dependent expression (Additional file 2).
Of the 1036 genes exhibiting a dose-dependent response
at 3 × 24 hrs and of the 738 differentially expressed genes
at 3 × 24 hrs in the time course study, 691 genes (94%)
were in common, demonstrating good reproducibility
between experiments.
Differentially expressed genes were associated with cell
growth and proliferation, cytoskeletal organization, extra-
cellular matrix modification, nucleotide synthesis, DNA
replication, protein synthesis and turnover, lipid metabo-
lism, glycolysis and immunological responses. The tem-
poral changes in gene expression were best represented
using five k-means clusters: A) induced at 12 and 24 hrs,
B) induced and sustained from 24 – 72 hrs, C) induced
late at 72 hrs, D) repressed between 8 – 24 hrs and E)
repressed and sustained from 24 – 72 hrs (Figure 3). The
majority of TAM-elicited differential expression occurred
after 12 hrs with only 42 features (26 genes) exhibiting
differential gene expression between 2 and 8 hrs, in
marked contrast to EE studies where significant gene
expression changes occurred prior to 8 hrs [15,16,22]. The
Table 1: TAM- and EE-induced uterine morphometric changes
A)
Dose Response (3 × 24 hr)
TAM Dose (µg/kg) Luminal Epithelial Cell Height (µm) Luminal Circumference (mm) Avg. Number of Glandular Tubules
0 8.75 ± 0.86 0.77 ± 0.14 1
1 8.99 ± 1.00 0.72 ± 0.12 0
3 10.91 ± 2.97 1.17 ± 0.41 1
10 10.73 ± 1.15 1.17 ± 0.29 3
30 15.12 ± 1.55* 1.87 ± 0.26* 5*
100 24.58 ± 2.79* 3.60 ± 0.27* 10*
300 27.08 ± 3.79* 2.68 ± 1.19* 5*
1000 31.30 ± 2.25* 3.05 ± 0.73* 5*
100 EE 28.94 ± 3.35* +++a 4
B)
Time Course (100 µg/kg)
Time (hrs) Luminal Epithelial Cell Height (µm) Luminal Circumference (mm)
2 9.98 ± 1.68 0.79 ± 0.19
4 8.61 ± 1.58 0.80 ± 0.06
8 10.06 ± 2.50 0.96 ± 0.29
12 9.46 ± 1.28 0.99 ± 0.21
18 9.18 ± 1.03 1.29 ± 0.42
24 11.08 ± 1.94* 1.22 ± 0.42
3 × 24 28.61 ± 7.50* 2.85 ± 1.83*
* Statistically different from time matched vehicle (p < 0.05)
a Lumen larger than 100× field of view, accurate measurements could not be made at 40× magnification Time course vehicle samples are not 
significantly different from each other.BMC Genomics 2007, 8:151 http://www.biomedcentral.com/1471-2164/8/151
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temporal pattern of differential gene expression correlates
with the histology results which indicate a delayed
response in comparison to EE.
Eleven genes, representative of affected pathways and
exhibiting different temporal gene expression patterns
(i.e. cytoskeletal organization (Krt2-4), signal transduc-
tion (Igf1), immunological responses (Il7), acid-base
homeostasis (Car3) and lipid transport (Fabp5, Vldlr)),
were verified by QRT-PCR and exhibited good agreement
with microarray results. Correlation coefficients ranged
from 0.46 to 0.97 (mean = 0.80) (Figure 4).
Immunohistochemistry (IHC) was also used to assess and
localize PCNA protein expression following TAM treat-
ment (Figure 5). Microarray results indicate a 2.5-fold
increase in Pcna transcript levels between 12 – 18 hrs after
treatment with IHC confirming elevated protein expres-
sion in epithelial and stromal cells in 12 hr TAM treated
samples when compared to time matched controls.
Comparison of common temporal TAM and EE gene 
expression data
Temporal TAM data were compared to an analogous EE
study using the same immature, ovariectomized C57BL/6
mouse model [16]. Employing the P1(t) > 0.999 and |fold
change| ≥ 1.5 criteria, 2657 unique annotated genes were
Immunohistochemical detection of differential Pcna protein  levels due to TAM Figure 5
Immunohistochemical detection of differential Pcna 
protein levels due to TAM. Twelve-hour vehicle (A) and 
TAM (B) treated uteri sections were immunohistochemically 
stained (NovaRED®) with Pcna specific antibodies. Treated 
samples have darker nuclear staining, indicating greater levels 
of Pcna protein expression, in agreement with the histologi-
cal assessment and changes in gene expression associated 
with cell proliferation. Increased Pcna expression is more 
pronounced in the luminal and glandular epithelium, and 
stroma (arrows). Tissues were counter-stained with hema-
toxylin. Images are representative of four biological repli-
cates. Bars represent 20 µm.
Tamoxifen-induced temporal gene expression patterns Figure 3
Tamoxifen-induced temporal gene expression pat-
terns. Five k-means clusters best represent the general tem-
poral patterns for the 2941 features differentially expressed 
following TAM treatment. Note the 8 hr delay in gene 
expression response especially in comparison to EE elicited 
gene expression [16] is speculated to be due to the delayed 
absorption of TAM. Inset numbers indicate the number of 
features represented by each cluster. Black pseudolines indi-
cate the general profile represented within each cluster.
Quantitative real-time PCR verification of selected TAM- induced genes Figure 4
Quantitative real-time PCR verification of selected 
TAM-induced genes. Overall, the microarray results for 
14 TAM- and EE-induced genes were verified using QRT-
PCR. The verified genes represent various affected pathways 
and different temporal patterns of expression. Overall, there 
was good correlation (average ρ = 0.8) between microarray 
(lines) and QRT-PCR (bars) data. Examples for six of the 
genes are illustrated. Statistically significant QRT-PCR differ-
ences (p < 0.05, n = 4) due to treatment are denoted by an 
asterisk (*).BMC Genomics 2007, 8:151 http://www.biomedcentral.com/1471-2164/8/151
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differentially expressed following treatment with 100 µg/
kg EE, of which 1209 were also activated by TAM (Addi-
tional file 3). Agglomerative hierarchical clustering of
common genes by treatment and time indicates that the
12 hr TAM response is most similar to the 4 hr EE
response, followed closely by 8 hr TAM (Figure 6). Inter-
estingly, TAM and EE exhibit similar gene expression pro-
files at 24 and 72 hrs, suggesting that the delay in some
TAM-elicited responses is not maintained at later time
points.
Expression profiles were compared for the 1209 differen-
tially expressed genes that were regulated by TAM and EE.
These genes were categorized as Similar, more Efficacious
by EE or TAM, or Ambiguous (Table 2). A total of 793
genes (66%) exhibited expression profiles that were simi-
lar in pattern and efficacy when a temporal shift, due to
delayed TAM response, was considered. Interestingly, 28
genes that were differentially expressed at least 2-fold
more by EE when compared to TAM (i.e., EE Efficacious
genes) were associated with cell growth, regulation of
transcription and protein metabolism and transport
including Fos (6.4-fold by EE; 4.1-fold by TAM) and Inhbb
(7.6-fold by EE; 3.2-fold by TAM). These genes are
involved in cell cycle regulation and cellular growth,
respectively, and possibly support the greater physiologi-
cal effect exhibited by EE. In contrast, 19 genes were mod-
ulated 2-fold or greater by TAM, including Sfn (3.6-fold by
EE; 5.5-fold by TAM), which is associated with prolifera-
tion inhibition. In general, efficacious TAM elicited
responses were associated with receptor-mediated signal
transduction, ion transport and protein metabolism.
Gene expression comparisons between the two studies
were also verified by QRT-PCR. As previously reported,
gene expression data is subject to compression [23], and
therefore the sensitivity of QRT-PCR data is often greater
when compared to microarray data. Thus, some genes
classified as Similar may also be classified as EE- or TAM-
Efficacious. For example, microarray data suggested that
Cdkn1a response to TAM and EE were comparable, but
through QRT-PCR EE induced an 8-fold response com-
pared to a 3.5-fold induction by TAM (Figure 7).
TAM and EE responsive genes were also examined for
estrogen response elements (EREs) in their promoter
regions by comparison to a list of computationally identi-
fied sequences [24]. EREs were found in 176 TAM-active
genes and 218 EE-active genes, with 133 regulated by both
compounds. Only 10% of TAM or EE differentially
expressed genes possessed an ERE suggesting that other
trans-acting factors may also be involved or that EREs were
outside of the search regions. Annotation information in
public repositories is constantly evolving, thus gene
names may have changed or new genes may have been
Table 2: Classification of TAM and EE commonly active annotated features
Classification Category Definition Number of Annotated Genes
Total Features 1209
Similar (S) Similar profiles exhibit patterns which are comparable in direction and magnitude across time; 
this also takes into account temporally shifted responses.
793
EE Efficacious (EEf) Potent responses demonstrate similar directional responses, but one compound elicits a 
greater induction or repression, by at least 2-fold, than the other; this category also includes 
temporally shifted responses.
28
TAM Efficacious (TEf) 19
Ambiguous (A) Gene pairs which did not fall into the previous four categories were labeled as Ambiguous 369
Temporal comparison of genes commonly activated by TAM  and EE Figure 6
Temporal comparison of genes commonly activated 
by TAM and EE. Hierarchical clustering of 1209 TAM- and 
EE-regulated genes (y-axis) identifies subsets of similar pro-
files according to time and treatment (x-axis). The dendro-
gram indicates that early responses (4 hrs) to 
ethynylestradiol (E) are most similar to 8 and 12 hrs 
tamoxifen (T) responses demonstrating temporally displaced 
TAM activation consistent with the delayed absorption of 
TAM. However, temporal displacement of TAM elicited 
responses is not maintained as EE and TAM responses clus-
ter together at 24 and 72 hrs.BMC Genomics 2007, 8:151 http://www.biomedcentral.com/1471-2164/8/151
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added since the publication. As a result, some genes may
be misclassified regarding their ERE status.
TAM- and EE-specific gene expression data
Gene expression changes unique to either TAM or EE may
be another factor contributing to their different utero-
trophic responses. An additional filtering method was
used to identify genes more likely to be unique to EE treat-
ment which involved excluding an extended list of TAM-
regulated genes obtained by relaxing the TAM criteria to
P1(t) > 0.9 and |fold change| ≥ 1.4 from the standard cri-
teria (P1(t) > 0.999; |fold change| ≥ 1.5) of EE (Figure 8A).
The same approach was also used to obtain a list of genes
unique to TAM (Figure 8B). This ensures that those genes
significant in both treatments and approaching signifi-
cance in the other treatment are not considered as unique,
thus increasing the likelihood of identifying treatment-
specific differential gene expression responses. For exam-
ple, to identify unique EE responses, the 2417 differen-
tially expressed TAM genes that satisfy the P1(t) > 0.9 and
|fold change| > 1.4 were excluded from the 2657 differen-
tially expressed EE genes (P1(t) > 0.999; |fold change| ≥
1.5) to identify 240 genes unique to EE treatment (Fig. 8a;
Additional file 4). Similarly, genes more likely unique to
TAM were identified by excluding the 2175 differentially
expressed EE genes with a P1(t) > 0.9 and |fold change| >
1.4 that were in common with the 2235 differentially
expressed TAM genes (P1(t) > 0.999; |fold change| = 1.5)
to identify 60 genes more likely unique to TAM (Addi-
tional file 5). Treatment-specific responses exhibited pro-
files distinctly different in pattern and magnitude from
their counterpart (Figure 9) even when taking delays, due
to TAM, into consideration.
The pathways represented within unique EE-responsive
genes include apoptosis regulators (Bok and Pdcd6) and
Identification of unique EE and TAM differentially expressed  genes Figure 8
Identification of unique EE and TAM differentially 
expressed genes. Treatment specific differentially 
expressed genes were identified by excluding a list obtained 
using a more relaxed criteria (P1(t) > 0.9; |fold change| ≥ 1.4) 
for one treatment from the differentially expressed genes 
identified using the standard criteria (P1(t) > 0.999; |fold 
change| ≥ 1.5) of the second treatment to identify gene 
expression changes that were more likely to be unique to 
one treatment. (A) A liberal list of TAM-induced genes iden-
tified, using a relaxed criteria of P1(t) ≥ 0.9 and |fold change| 
≥ ± 1.4, was excluded from the EE differentially expressed 
gene list using the standard selection criteria of P1(t) ≥ 0.999 
and |fold change| ≥ ± 1.5 to identify 240 genes more likely to 
be differentially expressed by EE alone. (B) Using a similar 
approach, a list of 60 genes more likely to be differentially 
expressed by TAM alone was generated. Lists of EE and TAM 
specific genes are provided in Additional files 4 and 5.
Examples of TAM and EE differential gene expression classifi- cations Figure 7
Examples of TAM and EE differential gene expres-
sion classifications. Examples of representative genes clas-
sified as Similar or Efficacious based on microarray data only. 
QRT-PCR analysis confirmed the classifications of these 
genes. In some cases (e.g., Cdkn1a) a gene classified as Similar 
may also be classified as EE-Efficacious based on QRT-PCR 
results due to data compression inherent in microarray data. 
Statistically significant differences (p < 0.05, n = 4) due to 
treatment are denoted by an asterisk (*).BMC Genomics 2007, 8:151 http://www.biomedcentral.com/1471-2164/8/151
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water imbibition (Aqp8 and Slc22a7), consistent with the
physiological effects observed. Fewer unique TAM-
responsive genes were identified. There was not an over-
representation of any functional pathway consistent with
its weaker uterotrophic response. These data suggest that
differentially regulate subsets of genes exist that contrib-
ute to the distinctive uterotrophic response elicited by
each treatment.
Discussion
A comparative approach was used that integrates the gross
organ, histopathological, and morphometric uterine
effects of EE and TAM with their dose response and tem-
poral gene expression profiles to further elucidate the
molecular basis of the partial agonist activity of TAM.
TAM treatment induces a 5-fold increase in gross uterine
weight following three daily doses compared to an 11-
fold increase with EE. In addition, no significant water
imbibition was induced by TAM. These effects are well
documented and are the basis for the classification of
TAM as a partial agonist [6,19,20,25]. Moreover, TAM
induces a delayed increase in uterine weight when com-
pared to EE which may be partially attributed to its weaker
agonist activity but is more likely a reflection of slower
absorption [26-28]. In contrast, peak serum levels of EE
are detected within two hours of treatment [29].
At equi-efficacious doses of TAM and EE (i.e. 100 vs. 20
µg/kg, respectively), comparable effects on UWW, lumi-
nal circumference and glandular epithelial were observed
(data not shown), suggesting both treatments proceed
through similar changes to achieve uterotrophy. However,
at higher doses, TAM does not elicit a comparable gamut
of responses as seen with higher doses of EE. Surprisingly,
TAM increased luminal epithelial thickness [18], due to
cellular hypertrophy and hyperplasia, that was not signif-
icantly different from EE, but mediated a smaller increase
in luminal circumference with more endometrial glands
compared to EE. Although these results appear contradic-
tory, glandular epithelium may arise from the luminal
epithelium and appear as highly invaginated regions of
the lumen that generate a large secretory surface area [30].
Thus, despite fewer endometrial glands in EE samples, its
glandular area is greater due to the increased luminal glan-
dular surface area which was not observed in the TAM
treated samples.
Temporal tamoxifen-elicited gene expression profiles
were examined following a single dose as well as after
three daily doses of 100 µg/kg TAM. Only 9 features, rep-
resenting 6 annotated genes, exhibited differential expres-
sion at 2 and 4 hrs after TAM treatment compared to 1234
EE genes at the same time points [16], consistent with the
delayed histological effects. Of these early TAM responses,
only Esr1 and Car3 have been reported to be induced by
estrogen [16,31]. At 12 hrs, 683 genes were differentially
expressed in response to TAM, of which 541 genes were
also affected by EE between 2 and 8 hrs [16]. Agglomera-
tive hierarchical clustering suggests that genes affected by
TAM and EE exhibited comparable gene expression
changes despite the delay in TAM responses.
Genes regulated by TAM and EE represent a variety of
pathways including cell cycle regulation, cytoskeletal re-
organization, nucleotide metabolism, immune and com-
plement activation and lipid transport and metabolism,
and have previously been associated with eliciting the
uterotrophic response [15,16,22,32-34]. Similarities in
their gene expression profiles suggest that the utero-
trophic response involves a defined subset of genes medi-
ated by the ER. Furthermore, greater than 75% of TAM-
activated genes that possessed an ERE, were also activated
by EE. However, differences in efficacy and responsive
genes may partially explain uterotrophic response differ-
ences.
Despite temporal delays, many genes were regulated by
both EE and TAM. Most of these commonly active genes
exhibited comparable fold changes suggesting that they
do not significantly influence the magnitude of the utero-
trophic response. For instance, both treatments equally
repressed uterotrophic supportive pro-apoptotic caspases
(Casp2  and  Casp6) (reviewed in [35]). Although these
genes were responsive to EE and TAM, others demon-
Temporal expression profiles of TAM and EE-specific genes Figure 9
Temporal expression profiles of TAM and EE-specific 
genes. Graphical representation of genes exhibiting com-
pound-specific responses demonstrated profiles which were 
distinctly different in pattern and magnitude compared to its 
non-responsive counterpart. These examples further illus-
trate that the filtering conditions used were adequate to 
identify differential responses by TAM and EE.BMC Genomics 2007, 8:151 http://www.biomedcentral.com/1471-2164/8/151
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strated quantitative differences in their expression behav-
ior. Twenty-eight genes, including the proliferation
supportive genes Cdkn1a, Fos and Inhbb, exhibited greater
EE efficacy consistent with their previously reported estro-
gen-induced expression [36-38] resulting in a full utero-
trophic agonist response. In contrast, 22 genes more
highly induced by TAM included G2/M inhibitor (Sfn/14-
3-3σ), which has been associated with human endome-
trial carcinomas [39] to reduce proliferation. Many of
these quantitative differences in gene expression efficacy
are consistent with the potent agonist activity of EE and
the weak agonist activity of TAM.
There were also treatment-specific gene expression effects.
Tentatively, 240 and 60 modulated genes were identified
as unique to EE or TAM, respectively. In general, these
responses were consistent with uterotrophic activity elic-
ited by EE and TAM. For example, QRT-PCR verified the
early induction of mitotic gene, Anapc1 by EE (data not
shown). Also, the treatment specific repression of pro-
apoptotic Bcl-2 member, Bok, and the induction of Pdcd6,
an apoptosis regulator, associated with proliferating tis-
sues [40] are consistent with the greater efficacy of EE. Bok
has previously been shown to be EE responsive in uteri,
whereas Pdcd6 approached the statistical cut-off in a pre-
vious study [15]. For TAM, QRT-PCR confirmed decreased
expression of Sipa1  (data not shown), a repressed
response at 24 hrs associated with decreased proliferation
[41] that may reduce hyperplasia.
DNA synthesis and replication pathways were also differ-
entially regulated. Sustained up-regulation of dNDP
phosphorylating genes, Nme1 and Nme6 [42], suggest sal-
vage pathways are emphasized for nucleotide synthesis
rather than de novo processes where Prps1, the first step in
purine biosynthesis, is repressed during the same period.
These genes are similarly modulated by TAM and EE sug-
gesting that proliferation may deplete resources for de
novo synthesis. Only Nme1 has been previously shown to
be EE responsive in rodent uteri [15,16]. However, EE
uniquely inhibited the de novo pyrimidine synthesis gene,
Dhodh [18–72 hrs], and induced the nucleotide recycling
gene, Nt5m [18 and 72 hrs] [43] suggesting an involve-
ment of salvage pathways to support EE-induced prolifer-
ation which have not previously been reported to be
estrogen responsive.
Water imbibition is a characteristic uterine response to
estrogens involving the increased flow of water to the
lumen mediated by aquaporins and ion transporters [44].
It does not appear to be a factor in TAM-induced uterine
weight increases as blotted weights were not significantly
different from wet weights. Aqp1 and Aqp5 are comparably
regulated by TAM and EE, while Aqp8 induction was spe-
cific to EE (QRT-PCR verified, data not shown). Aqp8 is a
known contributor to water imbibition [45] and its EE-
specific response suggests it may play a larger role in the
process of a full uterotrophic response.
The lack of ion transporter regulation may also be a con-
tributing factor in the absence of TAM-induced water
imbibition. The EE induction of zinc transporter, Slc30a3
[12 hrs], which causes ion uptake into various vesicle
compartments [46,47] may facilitate stromal edema and
has been shown to be responsive to estrogen where it is
down-regulated in brain tissue [48]. Organic anion trans-
porter, Slc22a7, was repressed by EE from 18 – 72 hrs in
the uteri suggesting anion retention in the stroma that
may also be important for edema. Slc22a7 is an importer
in the basolateral membrane of kidney tubule epithelia
(reviewed in [49]), and is estrogen responsive in the kid-
ney [50].
Differential regulation of ATP production genes is also
consistent with the greater uterotrophic efficacy of EE.
Transcripts associated with oxidative phosphorylation
(OXPHOS) complex I, Ndufb8 [8–24 hrs], and complex
III, Uqcr [8–18 hrs] and Uqcrh [4–18, 72 hrs], were all up-
regulated. Although not previously been reported as
responsive, collectively, the EE modulation of OXPHOS
components is consistent with greater energy demands
required to support increasing hypertrophic and hyper-
plastic activity induced by EE compared to TAM.
Other TAM gene expression studies have been conducted
using in vitro breast cancer models, primarily MCF-7 cells.
Comparisons of differentially expressed gene lists identi-
fied minimal to no overlap of TAM responses between in
vitro  human breast tissue and in vivo mouse uterus
[51,52]. Only the induction of Uqcrb [53], Nqo1 [54], Tff1,
Mapt [55], Pctk3, Wnt4 [56], Myb, Cdc6, Cdc20, Mcm2, Fos
and  Mybl2  [57] and repression of Xrcc1,  Tgfa  [54],
Rap1ga1, Blnk, Tm4sf1, Matn2, Ifi30, Tgfb3 and Smpd1 [55]
correlated with the changes observed in the current study.
Moreover, there are examples of divergent gene expression
changes such as inverse responses for Pfn2  [54],  Ctsh,
Selenbp1, Nfrkb, Cyp1a1 [55], Prps1 and Tmsb4x [56]. The
long term uterine effects of TAM have also been examined
in mice following neonatal exposure. Mice were treated
for four consecutive days after treatment and uteri sam-
ples examined at various months after dosing [58]. Col1a1
exhibited persistent up-regulation months after treatment
and was also induced in our short term study. Several fac-
tors, in addition to model differences, likely contribute to
the minimal overlap including differences in array plat-
forms and genome coverage, study design, and data anal-
ysis. For example, E2 and 4OH-TAM were utilized in the
in vitro studies while EE and TAM were administered to
the mice.BMC Genomics 2007, 8:151 http://www.biomedcentral.com/1471-2164/8/151
Page 10 of 15
(page number not for citation purposes)
Despite the minimal overlap between the models, the
activities of TAM, when compared to E2 were comparable.
In vitro and in vivo, the gene expression changes elicited by
4OH-TAM were similar to those mediated by E2 in MCF-
7 cells. Furthermore, the magnitude of gene expression
changes due to 4OH-TAM was attenuated compared to E2
[55,57]. Although 4OH-TAM and EE induced similar cell
cycle genes, other down-stream mechanisms were also
regulated to prevent 4OH-TAM mediated cell cycle pro-
gression [57]. Some of these mechanisms may play a roll
in the partial uterotrophic response elicited by TAM in
treated mice.
Differences in chemical structure may also contribute to
ligand specific responses. TAM belongs to the stilbene/
triphenylethylene family while EE is steroidal. Each has
unique binding modes resulting in different ER conforma-
tions [3], binding affinities [59,60], ligand-induced bind-
ing domain topographies [61], coactivator recruitment
capabilities [62,63], gene-specific thresholds of activation,
and efficacies [64]. Specifically, 4OH-TAM induces a dif-
ferent conformational change in the ER compared to E2,
influencing interactions with different coactivators. Elec-
trophoretic mobility shift assay and crystallographic
examination [65] have shown that 4OH-TAM-bound ER
could not bind a GRIP1 coactivator LXXLL peptide due to
helix-12 interference at the binding cleft, which was
recruited by E2. Consequently coactivator recruitment
may influence receptor complex interactions with
response element variants [66] which has been shown
with other structurally diverse ligands and nuclear recep-
tors [67,68].
In addition, differences in absorption, distribution,
metabolism and excretion (ADME) between ligands and
species, likely contribute to divergent physiological and
gene expression characteristics. It is well documented that
TAM metabolism differs significantly between humans
and rodents, for example, TAM N-oxide, 4OH-TAM and
DMT are the predominant metabolites in the mouse,
while DMT is the major human metabolite in microsomal
studies [28,69,70]. In rodents, the levels and rates of TAM
metabolism to 4OH-TAM and DMT were significantly dif-
ferent in the rat and mouse, where the rat metabolite pro-
file more closely resembles human profiles [28].
A cytochrome P450 2D6 polymorphism in humans fur-
ther illustrates the potential effects of differences in
metabolism on TAM activity. 4-OH-N-desmethylta-
moxifen (endoxifen) is a recently identified TAM metabo-
lite, found at higher levels than 4OH-TAM in patient
serum, generated by CYP2D6 activity. It exhibits similar
ER binding affinity, and comparable breast cancer cell
proliferation and estrogen-induced pS2 mRNA expression
inhibition activities compared to 4OH-TAM [4]. How-
ever, patients expressing specific CYP2D6 polymorphisms
(i.e., CYP2D6*3, *4, *5 and *10) that impaired or abol-
ished CYP2D6 metabolism have a nearly 2-fold higher
risk of breast cancer recurrence [71]. Collectively, these
studies illustrate the significant differences in TAM metab-
olism between models that compromise the extrapolation
of rodent data for use in human risk assessment.
Conclusion
Despite the comprehensive time course and dose
response studies, a complete assessment of the gene
expression effects and their roles in uterine responses
could not be achieved due to limited genome coverage on
our custom cDNA arrays and incomplete functional anno-
tation for the represented genes. However, comparative
TAM and EE studies using comparable designs and mod-
els identified conserved functionally annotated gene
expression changes that are consistent with the measured
uterotrophic response. Qualitatively, TAM and EE gene
expression profiles are similar; however, there are quanti-
tative differences in efficacy, consistent with the partial
agonist activity of TAM. Despite the evidence for these
qualitative and quantitative differences in gene expres-
sion, demonstration that these changes have causal roles
in the partial uterotrophic response elicited by TAM is
required. The relevance of the differences between estro-
gen and TAM and the association with endometrial cancer
[9,72,73] also needs further investigation.
Methods
Animal husbandry and treatment
Female C57BL/6 mice, ovariectomized by the vendor on
postnatal day (PND) 20, were obtained from Charles
River Laboratories (Raleigh, NC) on PND 25. Groups of
five mice were housed in polycarbonate cages bedded
with cellulose fiber chips (Aspen Chip Laboratory Bed-
ding, Northeastern Products, Warrensberg, NY) in a 23°C
environment with 30–40% humidity and a 12 h light/
dark cycle (0700 – 1900 h). Animals had access to deion-
ized water and Harlan Teklad 22/5 Rodent Diet 8640
(Madison, WI) ad libitum and acclimatized for 4 days prior
to treatment. For the dose response study, animals (n = 5)
were orally gavaged with 0.1 mL of 1, 3, 10, 30, 100, 300
or 1000 µg/kg b.w. tamoxifen (≥ 99% pure, trans-2- [4-
(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethyl-
amine) (Sigma Chemicals, St. Louis, MO), 100 µg/kg b.w.
17α-ethynylestradiol (EE; 17α-Ethynyl-1,3,5(10)-
estratriene-3,17β-diol) (Sigma) or sesame oil vehicle
(Sigma) alone. Standard uterotrophic regimen was fol-
lowed [12], consisting of three daily doses followed by
sacrifice 24 hrs after the final treatment, (3 × 24 hrs).
Doses were prepared based on average animal weight. For
the time course study, animals (n = 5) were orally gavaged
once or three times daily (3 × 24) with 100 µg/kg b.w.
TAM or vehicle alone and sacrificed at 2, 4, 8, 12, 18 andBMC Genomics 2007, 8:151 http://www.biomedcentral.com/1471-2164/8/151
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24 hrs after treatment in addition to 3 × 24 hrs treatment
group. Animals were sacrificed by cervical dislocation and
animal body weights were recorded. The uterus was
transected at the border of the cervix, and stripped of
extraneous connective tissue and fat. Whole uterine
weights were recorded before (wet weight) and after blot-
ting (blotted weight) under pressure with absorbent tis-
sue. A 6–8 mm section of uterine horn was not blotted
and placed in 10% neutral buffered formalin (NBF) for
histological preparation while the remainder was snap
frozen in liquid nitrogen and stored at -80°C for RNA
extraction. All procedures were performed with the
approval of the Michigan State University All-University
Committee on Animal Use and Care.
Histological processing, morphometric and pathological 
analysis
Samples stored in 10% NBF were allowed to fix for at least
24 hrs at room temperature then placed into tissue cas-
settes and stored in 30% ethanol holding solution at 4°C.
Paraffin embedding, 5 µm sectioning, mounting and
hematoxylin and eosin staining were completed by the
Michigan State University Laboratory for Anatomical His-
tology and Molecular Sciences according to standard tech-
niques [74]. Pathological assessments were evaluated
according to standardized National Toxicology Program
(NTP) pathology codes.
Morphometric analysis was performed on midhorn uter-
ine cross sections for all animals (n = 5 per treatment
group) using Scion Image analysis software (Scioncorp,
Frederick, MD). Histological markers of uterotrophy,
including luminal epithelial cell height (LECH), luminal
circumference and number of endometrial glands were
quantified for each slide. Statistical analysis of morpho-
metric data was assessed by Dunnett's or two-way ANOVA
followed with Tukey's HSD post hoc analysis to examine
dose dependent and temporal effects, respectively (SAS
version 9.1).
RNA isolation
Briefly, 1.0 mL of Trizol (Invitrogen, Carlsbad, CA) was
added to the frozen uterine tissue in a 2.0 mL microfuge
tube and homogenized in the presence of steel beads by a
Mixer Mill 300 homogenizer (Retsch, Germany). Total
RNA was isolated and extracted according to the manufac-
turer's protocol and resuspended in The RNA Storage
Solution (Ambion, Austin, TX). RNA samples were quan-
tified spectrophotometrically (A260) and assessed for qual-
ity by A260/A280 ratio as well as inspected using denaturing
agarose gel electrophoresis.
Microarray hybridization and analysis
Custom in-house cDNA arrays consisting of 13,361 fea-
tures, representing 7,952 unique genes (Unigene Build
144), were spotted on epoxy coated glass slides (SCHOTT
Nexterion, Germany) using an Omnigrid arrayer (Gen-
eMachines, San Carlos, CA) and Telechem Chipmaker 3
pins in a TeleChem CHP3 printhead head (Telechem
International Inc., Sunnyvale, CA) by the Research Tech-
nology Support Facility at Michigan State University [75].
Selected clones were obtained from EPAMAC [76],
Research Genetics, the National Institute of Aging and
Lion Biosciences. Detailed protocols for processing of
microarrays are available at [77].
An independent reference study design was used to assess
treatment effects [14]. For the dose response study, each
treatment group was hybridized to a single vehicle pool
utilizing 14 arrays, including dye swaps, and 3 biological
replicates for a total of 42 arrays. For the time course
study, each time-matched treated and vehicle sample was
competitively hybridized utilizing 14 arrays, including
dye swaps with 3 biological replicates for a total of 42
arrays. The Genisphere 900 3DNA Array Detection (Geni-
sphere Inc., Hatfield, PA) indirect incorporation kit was
used to generate cDNA samples for hybridization. Briefly,
1 µg of RNA was reverse transcribed in the presence of an
oligo-tagged primer specifically targeted for Cy3- or Cy5-
conjugated dendrimers. The cDNA was resuspended in 58
µL of 2X Formamide-Based Hybridization Buffer and
hybridized overnight on arrays sealed in a light-shielded,
humid chamber submerged in a 42°C water bath incuba-
tion. Slides were then washed in SSC solutions containing
decreasing concentrations of SDS, spin-dried and re-
hybridized with a Cy3:Cy5 (1:1) dendrimer mixture in
formamide based buffer to indirectly incorporate dyes at
the Cy3- and Cy5-dendrimer-tagged cDNA hybridized on
the first day. Slides were washed and dried as previously
described, and scanned at 635 nm (Cy3) and 532 nm
(Cy5) using a 428 Affymetrix Scanner (Santa Clara, CA).
Images were examined, features identified and intensity
values recorded using GenePix v.5.1 (Molecular Devices).
Microarray quality control, statistical analysis and gene 
list filtering
All arrays in this study were compared to a historical data
set of high quality arrays. Parameters assessed included
background signal intensity, feature signal intensity, fea-
ture vs. background signal intensity ratios, the number of
features with background intensities greater than the fea-
ture intensity for each array, and relationships between
feature and background signal intensities. All arrays sur-
passed the quality control parameters established in this
laboratory [78].
Data were normalized using a semi-parametric approach
[79] and model-based t-values were calculated comparing
time-matched treated and vehicle samples. Posterior
probabilities of activity [P1(t)-value] were then calculatedBMC Genomics 2007, 8:151 http://www.biomedcentral.com/1471-2164/8/151
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on a per-gene and per-time point basis using an Empirical
Bayes analysis [80]. Gene lists were initially filtered based
on posterior probability (P1(t) > 0.999) and fold-change
cut-off (|fold change| > ± 1.5) resulting in an active gene
list on which further functional analysis was conducted.
All raw and analyzed data were stored in dbZach [77], a
Minimum Information About Microarray Experiments
(MIAME)-supportive relational database [81] running
under Linux/Oracle 10 g. dbZach currently supports
microarray data storage, retrieval, and querying as well as
facilitates data analysis, sharing and reporting [82].
Active gene lists exclusive to TAM and EE were also gener-
ated. Data for the EE time course has previous been pub-
lished [16]. The TAM unique gene list was generated based
on relaxed criteria (P1(t) > 0.9 and |fold change| > ± 1.4
cut-off) to obtain a liberal EE-mediated gene list which
was then excluded from the original TAM unique gene list
using P1(t) > 0.999 and |fold change| > ± 1.5 criteria. The
EE unique gene list was generated using a reciprocal
approach (i.e., relaxed criteria (P1(t) > 0.9 and |fold
change| > ± 1.4 cut-off) to obtain a liberal TAM-mediated
gene list which was then excluded from the original EE
unique gene list using P1(t) > 0.999, and |fold change| >
± 1.5 criteria). This approach ensured that genes margin-
ally missing the cut-offs were not included in the com-
pound-unique list.
Estrogen response element searches were completed by
comparing Gene Symbols to the computationally identi-
fied list compiled by Bourdeau et al. [24].
QRT-PCR
Aliquots of RNA isolated from each of the five replicates
were set aside for SYBR™ Green quantitative real-time PCR
(QRT-PCR) verification. EE-treated, temporal mouse uteri
RNA were previously isolated [16]. An oligo-dT anchored
Superscript II (Invitrogen) reverse transcriptase reaction
was carried out on 1 µg of RNA, in a 20 µL reaction, from
each biological sample as per manufacturer's instructions.
Samples were diluted four-fold and 3 µL used in a 30 µL
real-time reaction mix containing 1X SYBR Green PCR
buffer, 3 mM MgCl2, 0.33 mM dNTPs, 0.5 IU AmpliTaq
Gold (Applied Biosystems, Foster City, CA) and 0.15 mM
forward and reverse primer. All primers were designed by
submitting cDNA microarray clone sequences into
Primer3 [83] to obtain an amplicon of approximately 125
bp (Additional file 6). PCR amplification was conducted
in 96-well MicroAmp Optical plates (Applied Biosystems)
on an Applied Biosystems PRISM 7000 Sequence Detec-
tion System under the following conditions: 10 min dena-
turation and enzyme activation at 95°C, followed by 40
cycles of 95°C for 15 s and 60°C for 1 min. After amplifi-
cation, a 30 min dissociation protocol was conducted to
assess primer specificity and product uniformity. Each
plate contained duplicate standards of purified PCR prod-
uct of known template concentration over eight orders of
magnitude to generate a log template concentration
standard curve. No template controls (NTC) samples were
included on each plate such that experimental samples
within 2 standard deviations of the NTCs are considered
below the limits of detection. Plots were visualized and
thresholds determined using ABI Prism 7000 SDS Soft-
ware (Applied Biosystems). Results were normalized to a
geometric mean of beta-actin (Actb), glyceraldehydes-6-
phosphate dehydrogenase (Gapd) and hypoxanthine gua-
nine phosphoribosyl transferase (Hprt) mRNA levels to
control for differences in RNA loading, quality and cDNA
synthesis. Statistical significance of expression differences
between vehicle and TAM treated samples were assessed
by two-way ANOVA followed by Tukey's HSD post hoc
analysis to examine treatment and treatment over time
effects (SAS version 9.1). Correlation analyses of QRT-
PCR and microarray data generated using the correlation
function of R v2.1.0.
Immunohistochemistry
Rabbit polyclonal antibodies specific for PCNA were pur-
chased from Abcam, Inc. (Cambridge, MA) and staining
localized using manufacturer's instructions for the
Vectastain Elite ABC Kit (Vector Laboratories, Burlingame,
CA). Briefly, paraffin-embedded uterine sections were
placed on glass slides, deparaffinized in xylene and re-
hydrated through a series of decreasing ethanol concen-
tration washes ending in ddH2O. Endogenous peroxi-
dases were quenched in 0.3% H2O2 in methanol solution
(30 min) followed by boiling (15 min) in a 10 nM
sodium citrate solution (pH 6.0) for antigen retrieval. To
minimize nonspecific background staining, sections were
blocked with normal goat serum (Vector Laboratories) for
20 min. The slides were incubated for 1 hr with the pri-
mary rabbit anti-PCNA polyclonal antibody (1:500 dilu-
tion in PBS), followed by 30 min each with biotinylated
goat anti-rabbit antibody (Vector Laboratories) (1:400)
and ABC reagent (Vector Laboratories). A single PBS rinse
was performed between incubations with each antibody.
Localization of antigen was obtained using Vector®
NovaRED (Vector Laboratories). The sections were coun-
terstained with hematoxylin.
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